Algernon Pharmaceuticals Inc.

Liste d'échange:

CSE

Statut:

Active

Industrie:

Life Sciences

Symbole:

AGN

Associated Securities:

Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Indice CSE:

Devise:

Vous êtes ici

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Information d'entreprise

Addresse

Suite 1500 - 1055 West Georgia Street

Vancouver, BC V6E4N7

Canada

Téléphone

604-398-4175

Courriel

info@algernonpharmaceuticals.com

URL

https://algernonpharmaceuticals.com

Date d’inscription à la cote

Lundi, février 1, 2016

Agent de transfert

TSX Trust Company

Vérificateur

Smythe LLP

Capitalisation

Capitalisation:

9,653,724

Réservé à l'émission:

4,968,996

Communiqués de presse

21/03/2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

02/03/2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Bulletins

27/03/2023

2023-0337 - Nouvelles Inscription - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

le 27 mars/March 2023

Bulletins

27/03/2023

2023-0337 - Nouvelles Inscription - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

le 27 mars/March 2023

01/03/2023

2023-0303 – Fractionnement des Actions - Algernon Pharmaceuticals Inc. (AGN)

le 1 mars/March 2023

Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional shares for each share held on such date.

18/11/2021

2021-1131 – Consolidation - Algernon Pharmaceuticals Inc. (AGN)

Le 18 novembre/November 2021

Algernon Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every one hundred (100) pre-consolidated common shares.

As a result, the outstanding shares of the company will be reduced to approximately 1,678,809 common shares.

The name and symbol will not change.

19/01/2021

2021-0122 - Expiration - Algernon Pharmaceuticals Inc. - Warrants (AGN.WT)

le 19 janvier/January 2021

Further to Bulletin 2020-1240, Algernon Pharmaceuticals Inc. warrants will expire on January 21, 2021.

Settlement Terms: All trades January 19^th and 20^th will settle for cash next day. Trades on January 21 will be for cash same day.

The warrants will be halted at noon and delisted at market close January 21, 2021.

29/12/2020

2020-1240 - Acceleration of Expiry Date – Algernon Pharmaceuticals Inc. - Warrants - AGN.WT

Le 29 décembre/December 2020

14/02/2019

2019-0226 – Changement de nom et de symbole - Breathtec Biomedical Inc. (BTH)

Le 14 février/February 2019

Breathtec Biomedical Inc. (BTH) has announced a name and symbol change to Algernon Pharmaceuticals Inc. (AGN).

Shares will begin trading under the new name and symbol on February 19, 2019.

16/10/2018

2018-1021 – Consolidation - Breathtec BioMedical Inc. (BTH)

Le 16 octobre/October 2018

Breathtec BioMedical Inc. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post-consolidation share for each two (2) pre-consolidation common shares.

As a result, the outstanding shares of the company will be reduced to approximately 28,682,012.

The shares will begin trading on a consolidated basis and with a new CUSIP number on October 17, 2018.

The name and symbol will not change.

Dépôts CSE

Fichier	Type	Date
Algernon Pharmaceuticals - Notice of Rights Offering	Autre	21/03/2023
Algernon Pharmaceuticals - Rights Offering Circular	Autre	21/03/2023
Algernon Pharmaceuticals - Confirmation of Mailing re forward stock split	Confirmation de dépôt	14/03/2023
Algernon Pharmaceuticals - Form 7 Monthly Report (February 2023)	Rapport d'activité mensuel	07/03/2023
Algernon Pharmaceuticals - Notice of Record Date for Stock Split	Consolidation des actions proposée	28/02/2023
Algernon Pharmaceuticals - Notice of Stock Split	Consolidation des actions proposée	28/02/2023
Algernon Pharmaceuticals - Form 7 Monthly Report (January 2023)	Rapport d'activité mensuel	07/02/2023
Algernon Pharmaceuticals - CFO certificate for quarter ended November 30, 2022	Autre	30/01/2023
Algernon Pharmaceuticals - CEO certificate for quarter ended November 30, 2022	Autre	30/01/2023

1
2
3
4
5
6
7
8
9
…
suivant ›
dernier »

Algernon Pharmaceuticals Inc.

Vous êtes ici

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Information d'entreprise

Capitalisation

Communiqués de presse

Algernon Pharmaceuticals Announces Launch of Rights Offering

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Bulletins

2023-0337 - Nouvelles Inscription - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Dépôts CSE

Algernon Pharmaceuticals - Notice of Rights Offering

Algernon Pharmaceuticals - Rights Offering Circular

Algernon Pharmaceuticals - Confirmation of Mailing re forward stock split

Algernon Pharmaceuticals - Form 7 Monthly Report (February 2023)

Algernon Pharmaceuticals - Notice of Record Date for Stock Split

Latest CSE News

Évènements à venir

Benzinga Cannabis Capital Conference

Connecte-toi avec nous:

Vous êtes ici

Algernon Pharmaceuticals Inc.

Vous êtes ici

Algernon Pharmaceuticals Inc. (AGN)

SEDAR Information

Formulaire de recherche

Information d'entreprise

Capitalisation

Communiqués de presse

Communiqués de presse

Bulletins

Bulletins

Dépôts CSE

Dépôts CSE

Latest CSE News

Évènements à venir

Connecte-toi avec nous: